Kairos Pharma, Ltd.

US$0.49As of Sun 8 Nov 2026, 12:00 UTC
AMEX:KAPAHealthcare
Country USA
PE (Fwd) •••
TSR 2Y CAGR (77.22%)
Div yield —
ROE (113.96%)
Biotechnology
Beta (5Y) 1.84
PE TTM —
TSR TTM (93.83%)
Mkt cap US$1.652M
ROIC (73.09%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.546
11.95%
207.47%
Hold 8|11|10|12|1
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.01
0.01
0.01
0.01
6.09%
20.61%
24.28%
26.50%
Revenue$M
0.093
0.097
0.101
0.102
9.75%
13.23%
15.02%
10.41%
Peers (US$1.652M)
Cap (US$)
PE
1.697M
—
1.575M
—
1.436M
—
Capital
TTM
5Y
10Y
Leveragex
0.238
(0.439)
(0.505)
EBIT/Intx
1.454
0.430
0.431
Own earn%
16.08
(53.59)
(61.31)
Sh yield%
20.28
27.68
27.79
Owners
Insiders/Inst%
7.50
70.99
Short interest%
4.61
SBC / revenue%
1.45
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
15
Op margin range%
0–2
$1 testx
−0.4
Incr. ROIC%
16